Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.

@article{Kao2011Phase1T,
  title={Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.},
  author={J. W. Kao and Eric M. Genden and Chien-Ting Chen and Michael Rivera and Charles C L Tong and Kryztof Misiukiewicz and Vishal Gupta and Vivek V. Gurudutt and Marita S. Teng and Stuart H. Packer},
  journal={Cancer},
  year={2011},
  volume={117 14},
  pages={3173-81}
}
BACKGROUND Concurrent inhibition of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) is an active and well tolerated regimen in recurrent head and neck cancer (HNC). In the current phase 1 trial, the authors sought to determine the maximum tolerated dose (MTD) and efficacy of concurrent erlotinib and celecoxib as a radiosensitizing regimen. METHODS Fourteen patients with previously irradiated HNC with no distant metastases who required reirradiation were eligible… CONTINUE READING